Glenmark Pharma's drug against Covid hits Indian markets

Glenmark Pharmaceuticals on Saturday launched antiviral drug Favipiravir for treatment of mild-to-moderate Covid-19 cases after it received the Indian drug regulator's approval. It will be available under the brand name FabiFlu as a prescription-based medication for Rs 103 per tablet, with a recommended dose of 1,800 mg twice a day on day 1 and 800 mg twice a day up to 14th day, according to the Mumbai-headquartered global pharmaceutical company.